InflaRx posts H1 loss as warrant fair-value hit outweighs FX gains, R&D spending falls

Reuters2026/08/06 11:57

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Inflarx posted a net loss of EUR 16.24 million for the six months ended June 30, 2026, reflecting a research-focused model with no product revenue.
Revenue fell to zero from EUR 39,432 due to the December 2025 halt of active GOHIBIC sales efforts in the US.
R&D expense declined to EUR 8.91 million from EUR 14.22 million, driven by lower third-party spend and reduced share-based compensation.
G&A expense dropped to EUR 5.73 million from EUR 8.34 million on lower legal and consulting costs, plus lower personnel expense.
Liquidity strengthened via a $150 million share offering, lifting available funds to EUR 158.4 million; runway projected into end-2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-031540), on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

InflaRx posts H1 loss as warrant fair-value hit outweighs FX gains, R&D spending falls

You may also like

Crypto prices